var title_f17_24_17792="Loop ileostomy";
var content_f17_24_17792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Loop ileostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 533px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A segment of intestine is brought out above the abdominal wall assuring a tension-free placement.",
"    <br>",
"     (B) An enterotomy is created along the efferent (or distal) end of the loop stoma.",
"     <br>",
"      (C) Using absorbable maturation sutures, an everting proximal afferent end (left) and a flush distal efferent end (right) are created. This will allow the effluent to come through the proximal spout into the collecting bag system and prevent leakage onto the surrounding skin. The distal flush end will allow venting.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17792=[""].join("\n");
var outline_f17_24_17792=null;
var title_f17_24_17793="Microwave endometrial ablation";
var content_f17_24_17793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Microwave endometrial ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bradley, LD. Microsulis Endometrial Ablation (MEA): Versatility to treat more patients. OBG Management 2005. Copyright &copy; 2005 Dowden Health Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17793=[""].join("\n");
var outline_f17_24_17793=null;
var title_f17_24_17794="Anal condyloma";
var content_f17_24_17794=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anal condyloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph shows the characteristic verrucous, pink or skin-colored, papilliform appearance of anal condyloma accuminata. In contrast, anal squamous cell carcinoma has a smooth and pearly appearance and may contain areas of hemorrhage and necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from the American Society of Colon and Rectal Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17794=[""].join("\n");
var outline_f17_24_17794=null;
var title_f17_24_17795="Secretin: Patient drug information";
var content_f17_24_17795=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Secretin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     see \"Secretin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=see_link\">",
"     see \"Secretin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ChiRhoStim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to see if the pancreas is working the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691637",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to see if there is a tumor in the pancreas or bowel.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to secretin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703172",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any irritation of the pancreas.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel disease such as Crohn's disease or ulcerative colitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11861 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17795=[""].join("\n");
var outline_f17_24_17795=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220255\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014128\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014127\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014132\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014133\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014135\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014130\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014137\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=related_link\">",
"      Secretin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/45/20179?source=related_link\">",
"      Secretin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_24_17796="Enalaprilat (intravenous): Patient drug information";
var content_f17_24_17796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Enalaprilat (intravenous): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"     see \"Enalaprilat (intravenous): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=see_link\">",
"     see \"Enalaprilat (intravenous): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13655454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vasotec&reg; I.V",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13683974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13683976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13683975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3614363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to enalaprilat or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries or hyperaldosteronism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13683980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13683981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13683982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13683978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13684022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13683984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17095 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17796=[""].join("\n");
var outline_f17_24_17796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13655454\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683974\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683976\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683975\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683980\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683981\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683982\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683978\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13684022\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13683984\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=related_link\">",
"      Enalaprilat (intravenous): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=related_link\">",
"      Enalaprilat (intravenous): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_24_17797="Angiofibroma Light";
var content_f17_24_17797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Angiofibroma of the head and neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of an angiofibroma; these tumors often have a stag-horn arrangement of thin-walled vessels (black arrow). The stroma is fibrotic and hypocellular.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17797=[""].join("\n");
var outline_f17_24_17797=null;
var title_f17_24_17798="Zopiclone: Drug information";
var content_f17_24_17798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zopiclone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/11/40116?source=see_link\">",
"    see \"Zopiclone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F236316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Zopiclone&reg;;",
"     </li>",
"     <li>",
"      CO Zopiclone;",
"     </li>",
"     <li>",
"      Dom-Zopiclone;",
"     </li>",
"     <li>",
"      Imovane&reg;;",
"     </li>",
"     <li>",
"      Mylan-Zopiclone;",
"     </li>",
"     <li>",
"      Novo-Zopiclone;",
"     </li>",
"     <li>",
"      Nu-Zopiclone;",
"     </li>",
"     <li>",
"      PHL-Zopiclone;",
"     </li>",
"     <li>",
"      PMS-Zopiclone;",
"     </li>",
"     <li>",
"      PRO-Zopiclone;",
"     </li>",
"     <li>",
"      RAN&trade;-Zopiclone;",
"     </li>",
"     <li>",
"      ratio-Zopiclone;",
"     </li>",
"     <li>",
"      Rhovane&reg;;",
"     </li>",
"     <li>",
"      Riva-Zopiclone;",
"     </li>",
"     <li>",
"      Sandoz-Zopiclone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F236353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Hypnotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F236320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypnotic:",
"     </b>",
"     Oral: 5-7.5 mg once daily at bedtime (maximum: 7.5 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Patients with chronic respiratory insufficiency:",
"     </i>",
"     Initial: 3.75 mg once daily at bedtime; may increase up to 7.5 mg/day with caution in appropriate cases. Use is contraindicated in patients with severe respiratory function insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Debilitated patients:",
"     </i>",
"     Initial: 3.75 mg once daily at bedtime; may increase up to 7.5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F236321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: 3.75 mg once daily at bedtime; may increase up to 7.5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13253309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Initial: 3.75 mg once daily at bedtime; may increase up to 7.5 mg/day.",
"     <b>",
"      Note:",
"     </b>",
"     Accumulation of zopiclone or its metabolites is not anticipated. The manufacturer labeling however recommends an initial dose reduction.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F236322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment: Initial: 3.75 mg once daily at bedtime; may increase up to 7.5 mg/day with caution in appropriate cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet, oral: 5 mg, 7.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F236295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer just before bedtime.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F236294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term and symptomatic relief of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F236351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggressiveness, agitation, anterograde amnesia, anger, anxiety, chills, complex sleep-related behaviors, confusion, depression, difficulty awakening,  dizziness, drowsiness, euphoria, hallucinations, headache, hostility, irritability, memory impairment, nervousness, nightmares, somnolence, speech abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatological: Angioedema, pruritus, rash, spots on skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite increased, constipation, coated tongue, diarrhea, dry mouth, dyspepsia, halitosis, nausea, taste alteration (bitter taste), vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Coordination impaired, hypotonia, limb heaviness, muscle spasms, paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F236298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zopiclone or any component of the formulation; severe respiratory impairment (eg, sleep apnea); myasthenia gravis; severe hepatic insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F236281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abnormal thinking/behavioral changes: Increased daytime anxiety and/or restlessness have been observed with use; effects may be related to drug&rsquo;s short half-life. Hypnotics/sedatives have also been associated with abnormal thinking and behavior changes including decreased inhibition, aggression, bizarre behavior, agitation, hallucinations, and depersonalization. These changes may occur unpredictably and may indicate previously unrecognized psychiatric disorders; evaluate appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines and benzodiazepine-like agents have been associated with anterograde amnesia; zopiclone should not be administered unless a full night's sleep is possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression impairing physical and mental capabilities; patients must be cautioned about performing tasks which require mental alertness (operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Angioedema and signs of anaphylaxis have been reported (rarely) with administration, including after the initial dose. Patients developing angioedema should discontinue therapy and should not be rechallenged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression; worsening of depression, including suicidal ideation, has been reported with the use of hypnotics. Intentional overdose may be an issue in this population; prescribe least amount of medication needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse, alcoholism, or significant personality disorders; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use. The risk of dependence increases with higher dosage and longer duration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; dosage adjustment recommended. Use is contraindicated in severe hepatic insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with chronic respiratory disease. Use is contraindicated in patients with severe respiratory insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Use with caution in patients taking strong CYP3A4 inhibitors and/or inducers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; more susceptible to adverse reactions (eg, agitation, anorexia, anxiety, anterograde amnesia, confusion, falls).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage forms specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Some formulations may contain lactose; avoid use in patients intolerant to galactose (eg, glucose-galactose malabsorption or galactosemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Use should generally not exceed 7-10 days. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness; complete re-evaluation of the patient should occur when treatment is required for &gt;2-3 consecutive weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid onset: Because of the rapid onset of action, administer immediately prior to bedtime or after the patient has gone to bed and is having difficulty falling asleep.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause acute withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F236348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F236285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Zopiclone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F236312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Effect/toxicity may be increased by grapefruit juice; avoid concurrent use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F236301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is insufficient data on safety in pregnancy; however, benzodiazepines may cause congenital malformations during the 1st trimester and neonatal CNS depression during the last few weeks of pregnancy; it is expected zopiclone may do the same. Use is not recommended during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F236325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F236302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zopiclone is excreted in human milk and its concentration may reach 50% of plasma levels; therefore, it is not recommended to use while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F236290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for confusion, excessive drowsiness (especially in elderly), and/or respiratory depression. Monitor patients with hepatic insufficiency or with chronic respiratory insufficiency closely.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F236303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amoban (JP);",
"     </li>",
"     <li>",
"      Datolan (ES);",
"     </li>",
"     <li>",
"      Docilen (PE, PY, UY);",
"     </li>",
"     <li>",
"      Dopareel (HK);",
"     </li>",
"     <li>",
"      Dormex (PE);",
"     </li>",
"     <li>",
"      Eurovan (HK);",
"     </li>",
"     <li>",
"      Genclone (TW);",
"     </li>",
"     <li>",
"      Imovane (AR, AU, BB, BE, BM, BR, BS, BZ, CH, CL, CN, CO, CZ, DK, EE, FI, FR, GR, GY, HK, HN, HU, IL, IT, JM, KP, LU, MX, MY, NL, NO, NZ, PL, RU, SE, SG, SR, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Imrest (AU);",
"     </li>",
"     <li>",
"      Insopin (MY);",
"     </li>",
"     <li>",
"      Nocturno (IL);",
"     </li>",
"     <li>",
"      Optidorm (DE);",
"     </li>",
"     <li>",
"      Sedolox (AT);",
"     </li>",
"     <li>",
"      Sedorm (CO);",
"     </li>",
"     <li>",
"      Siaten (ES);",
"     </li>",
"     <li>",
"      Somnol (HN);",
"     </li>",
"     <li>",
"      Somnols (EE);",
"     </li>",
"     <li>",
"      Somnosan (DE);",
"     </li>",
"     <li>",
"      Sonlax (BG);",
"     </li>",
"     <li>",
"      Ximovan (DE);",
"     </li>",
"     <li>",
"      Z-Dorm (ZA);",
"     </li>",
"     <li>",
"      Zetix (CN, EC);",
"     </li>",
"     <li>",
"      Zimoclone (IE);",
"     </li>",
"     <li>",
"      Zimovane (GB);",
"     </li>",
"     <li>",
"      Zolinox (IN);",
"     </li>",
"     <li>",
"      Zolon (MY, TW);",
"     </li>",
"     <li>",
"      Zometic (CN);",
"     </li>",
"     <li>",
"      Zomianne (TW);",
"     </li>",
"     <li>",
"      Zopimed (ZA);",
"     </li>",
"     <li>",
"      Zopinox (FI);",
"     </li>",
"     <li>",
"      Zopitran (IN);",
"     </li>",
"     <li>",
"      Zopivane (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F236280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zopiclone is a cyclopyrrolone derivative and has a pharmacological profile similar to benzodiazepines. Zopiclone reduces sleep latency, increases duration of sleep, and decreases the number of nocturnal awakenings.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F236297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~92-105 L; occurs rapidly from vascular compartment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4 and CYP2C8",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &gt;75%; Elderly: 94%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~5 hours; Elderly: ~7 hours; Hepatic impairment: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: &lt;2 hours; Hepatic impairment: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (75%; ~4% to 5% as unchanged drug); feces (16%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aranko K, Luurila H, Backman JT, et al, &ldquo;The Effect of Erythromycin on the Pharmacokinetics and Pharmacodynamics of Zopiclone,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1994, 38(4):363-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17798/abstract-text/7833227/pubmed\" id=\"7833227\" target=\"_blank\">",
"        7833227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Becquemont L, Mouajjah S, Escaffre O, et al, &ldquo;Cytochrome P-450 3A4 and 2C8 Are Involved In Zopiclone Metabolism,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 1999, 27(9):1068-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17798/abstract-text/10460808/pubmed\" id=\"10460808\" target=\"_blank\">",
"        10460808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zammit G, &ldquo;Comparative Tolerability of Newer Agents for Insomnia,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2009, 32(9):735-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17798/abstract-text/19670914/pubmed\" id=\"19670914\" target=\"_blank\">",
"        19670914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10126 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17798=[""].join("\n");
var outline_f17_24_17798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236316\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236353\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236320\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236321\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13253309\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236322\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076369\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234391\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236295\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236294\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236351\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236298\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236281\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236348\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236312\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236301\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236325\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236302\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236290\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236303\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236280\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236297\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10126|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/11/40116?source=related_link\">",
"      Zopiclone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_24_17799="Clonorchiasis sonogram";
var content_f17_24_17799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Clonorchiasis sonogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver sonograms of clonorchiasis.",
"    <br>",
"     (A) In a 57-year-old man, transverse scan of the left hepatic lobe, showing mild dilatation of the intrahepatic bile ducts (arrows).",
"     <br>",
"      (B) In a 56-year-old man with the increased periductal echogenicity (arrows) along the dilated intrahepatic bile ducts.",
"      <br>",
"       (C) Oblique scan of the gallbladder of a heavily-infected Chinese man with several floating echogenic foci (arrows), which probably indicate worms or desquamated materials.",
"       <br>",
"        (D) Mild dilatation of the intrahepatic bile ducts in the central liver of a cured 60-year-old man.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Choi D, Hong ST. Imaging diagnosis of clonorchiasis. Korean J Parasitol 2007; 45:77. Copyright &copy; 2007 Korean Society for Parasitology.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17799=[""].join("\n");
var outline_f17_24_17799=null;
var title_f17_24_17800="Treatment of acute gout";
var content_f17_24_17800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute gout",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/24/17800/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/24/17800/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/24/17800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/24/17800/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/24/17800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/24/17800/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/24/17800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gout is an intensely painful inflammatory arthritis that typically involves a single joint, but can affect multiple joints. The goal of therapy in an acute gout attack is prompt and safe termination of pain and disability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of gout\", section on 'Acute gouty arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Without therapy, acute gouty arthritis usually resolves within a few days to several weeks. However, symptoms improve more quickly with administration of any of a broad array of antiinflammatory drugs (",
"    <a class=\"graphic graphic_algorithm graphicRef65843 \" href=\"UTD.htm?24/44/25295\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptom resolution is more prompt and complete with early initiation of therapy.",
"   </p>",
"   <p>",
"    A number of drugs have been used for the treatment of acute gout, although randomized trial data is surprisingly limited [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"     </li>",
"     <li>",
"      Intraarticular or systemic glucocorticoids",
"     </li>",
"     <li>",
"      Interleukin 1 beta inhibition (investigational)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Upon resolution of the acute attack, the patient is said to have entered the intercritical (between attacks) period, which may or may not require prophylactic therapy to prevent recurrent gout and chronic tophaceous disease.",
"   </p>",
"   <p>",
"    The management of acute gouty arthritis will be reviewed here. The prevention of recurrent gout after resolution of the acute attack is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NSAIDS/COX-2 INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high-quality randomized, placebo-controlled trials of nonsteroidal antiinflammatory drugs (NSAIDs) for acute gouty arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/2\">",
"     2",
"    </a>",
"    ]. Nevertheless, they are first-line therapy for most patients with this disorder.",
"   </p>",
"   <p>",
"    Complete or nearly complete resolution of pain and disability typically occurs within several days to one week.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is usually avoided because of the paradoxical effects of salicylates on serum urate, resulting from renal uric acid retention at low doses (&lt;2 to 3",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and uricosuria at higher doses.",
"   </p>",
"   <p>",
"    A number of randomized trials have compared different NSAIDs with each other, without any apparent differences in efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. In the two largest trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    and the selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib had comparable efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Significant pain relief was noted at the initial assessment four hours after the first dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caution is necessary in patients with known cardiovascular disease or with multiple risk factors for atherosclerotic coronary disease, since an increased risk of myocardial infarction, stroke, and heart failure have been associated with use of both selective COX-2 inhibitors and, perhaps to a lesser degree, nonselective NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unless contraindicated (eg, by gastrointestinal, cardiovascular, or renal disease, or allergy), we suggest administration of a potent oral nonselective NSAID (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    ) for reduction of acute gouty inflammation, especially if treatment is initiated within 24 hours of the onset of symptoms (",
"    <a class=\"graphic graphic_algorithm graphicRef65843 \" href=\"UTD.htm?24/44/25295\">",
"     algorithm 1",
"    </a>",
"    ). A typical starting dose for naproxen is 500 mg twice daily and for indomethacin 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given in three divided doses.",
"   </p>",
"   <p>",
"    In view of the frequent gastrointestinal intolerance associated with NSAIDs, the dose should be reduced by one-half as soon as objective and subjective improvement is noted, often within three days. Further dose reductions and withdrawal over several more days is safe and practical. Most patients are on NSAIDs until the attack has completely resolved; this may be a total of seven to ten days.",
"   </p>",
"   <p>",
"    In an attack of several days duration a longer course of treatment may be necessary and an antiinflammatory agent with fewer gastroduodenal side effects (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"     nabumetone",
"    </a>",
"    or a selective COX-2 inhibitor) may be preferred. In patients at high risk of gastric ulcer or gastrointestinal bleeding addition of an antiulcer medication to a nonselective NSAID may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COLCHICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients report that incipient attacks can be aborted with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    taken at the first symptom. Whether, however, colchicine therapy offers more rapid or complete relief of gout flares than alternative antiinflammatory agents is not clearly established and awaits head-to-head comparisons of colchicine with NSAIDs, glucocorticoids, and IL-1 inhibitors.",
"   </p>",
"   <p>",
"    Despite centuries of use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    -containing products for treatment of the symptoms and signs of gout, oral colchicine (uncombined with another active ingredient) was approved for the first time by the US FDA in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    can be effective for the treatment of acute gouty arthritis, and side effects are less likely when a low-dose regimen is used at the onset of symptoms of flare [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/9\">",
"     9",
"    </a>",
"    ]. The regimen recommended by the FDA for administration of this agent (in the absence of concurrent use of interacting drugs or of end-stage renal",
"    <span class=\"nowrap\">",
"     disease/renal",
"    </span>",
"    dialysis) is a low-dose course consisting of 1.2 mg (2 tablets) at the first dose followed one hour later by 0.6 mg (1 tablet), to give a total dose of 1.8 mg on the first day of colchicine treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Traditional regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional regimen of 0.6 mg (one tablet) per hour or every two hours until there was either relief of gouty pain and inflammation, a total dose of 4 to 6 mg was reached, or GI symptoms occurred, was limited by adverse gastrointestinal effects (diarrhea, abdominal cramping, nausea, vomiting). As an example, in a placebo-controlled trial demonstrating efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , 43 hospitalized patients with acute gout flares were randomized to receive colchicine (1 mg followed by 0.5 mg every two hours as tolerated or until complete response) or placebo at a mean of 38 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/11\">",
"     11",
"    </a>",
"    ]. About two-thirds (73 percent) of colchicine-treated patients improved (&ge;50 percent pain relief on a pain VAS) at 36 to 48 hours from treatment initiation, compared with about one-third (32 to 36 percent) of the placebo group. However, all patients taking colchicine (mean total dose 6.7 mg) developed diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting at a median time of 24 hours and, in the majority of patients, GI symptoms occurred before or concomitant to pain relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lower dose regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unfavorable therapeutic index for traditional (higher dose) oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    treatment led to interest in lower-dose oral colchicine treatment. As an example, an alternative regimen was recommended by a task force of the European League Against Rheumatism (EULAR) Standing Committee for International Clinical Studies (2006) which was based on a consensus of expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/12\">",
"     12",
"    </a>",
"    ]. The EULAR guideline recommended colchicine 0.5 mg three times daily. And, as noted above (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Oral'",
"    </a>",
"    above), the US FDA approved a lower dose regimen for treatment of acute gout that consists of 1.2 mg at the first dose followed one hour later by 0.6 mg, for a total dose of 1.8 mg.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efficacy &ndash; Low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      may have similar efficacy to that of a higher dose regimen. This was the conclusion of the AGREE trial in which 575 patients with recurrent gout enrolled [",
"      <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/9\">",
"       9",
"      </a>",
"      ]. Of these, 184 patients with a validated flare of gout, who had been randomly assigned to low-dose, higher dose, or placebo groups received one of the following regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low-dose oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      &ndash; A total dose of 1.8 mg over one hour, followed by placebo hourly for five more hours, or",
"     </li>",
"     <li>",
"      Higher dose &ndash; An initial dose of 1.8 mg over one hour followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      0.6 mg for five additional hours (maximum total dose 4.8 mg)",
"     </li>",
"     <li>",
"      Placebo &ndash; The placebo group received placebo at all time points.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary comparison was the proportion of subjects in the high dose group versus those in the placebo group who achieved a &ge;50 percent pain reduction by 24 hours from treatment initiation (without the use of rescue medication) versus placebo. Comparison of the proportion of low-dose-treated subjects reaching endpoint versus placebo was an additional endpoint.",
"   </p>",
"   <p>",
"    Both the low- and higher-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    treatments had greater efficacy at 24 hours of treatment than placebo; 38 percent, 33 percent, and 16 percent. Pain reduction at 32 hours and exceeding two units at 24 and 32 hours were also significant for both colchicine-treated groups when compared with placebo.",
"   </p>",
"   <p>",
"    In all efficacy measurements, low-dose treatment appeared to have efficacy similar to higher-dose treatment. In fact, a smaller proportion of low-dose-treated subjects (but not higher-dose-treated subjects) took rescue medication than placebo-treated subjects, and pain reduction of all degrees was achieved by a higher proportion of low-dose than higher-dose- or placebo-treated subjects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adverse effects &ndash; In the AGREE trial (see above), differences in adverse GI events between the treatment groups were striking [",
"      <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/9\">",
"       9",
"      </a>",
"      ]. Subjects in the low-dose treatment group experienced diarrhea (23 percent) or other GI symptoms no more often than placebo-treated subjects (16 percent diarrhea) during the trial, but diarrhea occurred in 77 percent of higher-dose-treated subjects (odds ratio 21.3; CI 8-57). Diarrhea was graded as severe in 19 percent of high-dose treatment subjects versus 0 percent in the low-dose group, and vomiting was seen in 17 percent in the high-dose group but 0 percent in the other groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in both low- and higher-dose regimens has efficacy in the treatment of pain in acute gout flare, the GI toxicity of the high-dose regimen substantially reduces the benefit to risk ratio of treatment. In contrast, toxicity of low-dose treatment was not discernibly different from that of placebo, supporting recommendations for low-dose colchicine treatment in acute gout [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/8-10,12\">",
"     8-10,12",
"    </a>",
"    ] rather than higher-dose treatment.",
"   </p>",
"   <p>",
"    In patients on ongoing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    prophylaxis therapy who have an acute flare, a course of low-dose colchicine could be followed by return to the preceding prophylaxis dose on the day after low-dose flare treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When low-dose first day oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    treatment of acute flare is beneficial but the response is incomplete in a patient not receiving ongoing colchicine prophylaxis therapy, the guidelines for use of colchicine prophylaxis can be applied on subsequent days until resolution of the acute flare [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, when low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy is ineffective or minimally effective in suppressing acute gout in timely fashion, alternative antiinflammatory agents, including an intraarticular glucocorticoids, should be considered. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intravenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the potential for life-threatening adverse effects, the United States Food and Drug Administration in February 2008 asked that intravenous preparations containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    no longer be manufactured or shipped in the USA [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/13\">",
"     13",
"    </a>",
"    ]. Although existing intravenous preparations were not recalled, this cessation of supply severely limits, and effectively ends, the use of colchicine by the intravenous route in the USA.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is a consideration in hospitalized patients who are unable to take oral medications. However, as mentioned above, its use is limited by serious systemic reactions, including bone marrow suppression, hepatic necrosis, acute renal failure, disseminated intravascular coagulation, seizures, and even death. Severe sclerotic tissue reactions can occur in the event of colchicine extravasation, so secure intravenous access is essential.",
"   </p>",
"   <p>",
"    Precautions for the use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    have been published in an effort to reduce adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/14\">",
"     14",
"    </a>",
"    ]. In 20 reported deaths attributed to the use of intravenous colchicine, each patient received a cumulative dose that exceeded the recommended maximum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Absolute contraindications to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    therapy for acute gout include combined renal and hepatic disease, creatinine clearance below 10",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and extrahepatic biliary obstruction.",
"   </p>",
"   <p>",
"    An initial dose of 1 to 2 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    is typically given and, if necessary, another 1 mg dose is administered 6 to 12 hours later. The total intravenous dose should in no instance exceed 4 to 5 mg during any 24-hour period or during any attack [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the availability of multiple alternative approaches, we have had little occasion to use intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    in recent years. Although intravenous colchicine can reduce the inflammation of pseudogout, the potential dangers of this approach have led to withdrawal of approval in the United States for the distribution of colchicine for administration by the intravenous route.",
"   </p>",
"   <p>",
"    Where the intravenous preparation is still available, it should be considered only in hospitalized patients with polyarticular gout, or those unable to tolerate NSAIDs or take oral medications. Administration should be supervised by physicians experienced in intravenous use. Adherence to the precautions cited above is essential to avoid potentially life-threatening toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-drug interactions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    may occur. These occur largely with agents that interfere with the functions of the membrane P-glycoprotein multiple drug resistance transporter (P-gp)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the cytochrome P450 system component CYP3A4 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both P-gp and CYP3A4 are involved in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    metabolism and, when colchicine treatment is given along with agents inhibiting or utilizing these systems, there is the risk for severe or fatal outcomes. Use of colchicine with P-gp inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , azole antifungals, some calcium channel blockers, vinca alkyloids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , etc. [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/18\">",
"     18",
"    </a>",
"    ]) or strong CYP3A4 inhibitors (eg, protease inhibitors, macrolide antibiotics, azole antifungals, etc. [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/19\">",
"     19",
"    </a>",
"    ]) is contraindicated. Care should be taken in combining use of colchicine with the wider array of less strong CYP3A4 inhibitors, including statin and other lipid-lowering drugs (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy can be injected into the affected joint(s) or given systemically, either orally or parenterally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intraarticular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular (depot) glucocorticoids are a reasonable option in patients with only one or two actively inflamed joints, although evidence of their benefit has been limited to small, open label trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/20\">",
"     20",
"    </a>",
"    ]. We consider this option preferable to systemic glucocorticoids in patients who cannot take NSAIDs or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The diagnosis of acute gouty arthritis should be secure and infection must be ruled out before injection is considered. We typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 40 mg for knee joints and lower doses for smaller joints. Equivalent doses of depo-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    may also be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids may be administered orally in patients who cannot take NSAIDs or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    and who are not candidates for intraarticular glucocorticoid injection because of polyarticular disease.",
"   </p>",
"   <p>",
"    While the data on efficacy of oral glucocorticoids are limited, they support clinical experience that suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    in doses of 30 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (or other equivalent glucocorticoid) for one to two days, then tapered over seven to ten days, effectively reduces acute symptoms to a similar extent as do NSAIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/21\">",
"     21",
"    </a>",
"    ]. However, rebound attacks are relatively common once glucocorticoids are withdrawn, especially in patients who have previously suffered a number of prior attacks and whose intercritical periods have progressively shortened.",
"   </p>",
"   <p>",
"    In patients who cannot take oral medications, intravenous glucocorticoids or subcutaneous adrenocorticotropic hormone (ACTH) are options. Guidelines for the use of glucocorticoids in this setting are similar to those for oral therapy, but we generally do not favor their use in the treatment of acute gout unless intravenous access is already in place.",
"   </p>",
"   <p>",
"    In addition to stimulating release of corticosteroids, ACTH may act on melanocortin type 3 receptors on cells involved in gouty inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/22\">",
"     22",
"    </a>",
"    ]. Data on the efficacy of ACTH are limited. In one retrospective report, virtually all acute attacks resolved within 5.5 days of ACTH administration with few significant adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/23\">",
"     23",
"    </a>",
"    ]. More than one injection may be required.",
"   </p>",
"   <p>",
"    Various ACTH dosing regimens have been advocated. We have used 40 to 80 USP units, administered twice daily for two days and then once daily for several succeeding days as needed. Others have studied 40 units as a single injection, with reinjection as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/24\">",
"     24",
"    </a>",
"    ], or 25 units as a single injection when treating acute small joint monoarticular gout [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/25\">",
"     25",
"    </a>",
"    ]. Use of ACTH may be limited by availability and to avoid delay in administration, the hospital pharmacy, or formulary should be consulted before ordering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interleukin-1 inhibition (investigational)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-1 (IL-1) is an important mediator of inflammation and therapeutic target in acute gout. &nbsp;Monosodium urate crystals induce the release of proinflammatory cytokines from leukocytes, an action likely to contribute significantly to the symptoms of the acute gout flare. Among the cytokines involved is interleukin-1 beta (IL-1), which is released by monocytes and synovial mononuclear cells through innate immune mechanisms that include the toll like receptors TLR-2 and TLR-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/26\">",
"     26",
"    </a>",
"    ] and the inflammasome complex [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28344?source=see_link\">",
"     \"Pathophysiology of gouty arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibition of the interleukin-1 (IL-1) pathway by use of targeted biologic agents has been effective in patients with acute gout:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"      &mdash; IL-1 inhibition prevented peritoneal neutrophil accumulation in response to intraperitoneal injection of urate crystals in mice; the encouraging findings in this animal model led to an open label pilot study of the recombinant IL-1 receptor antagonist, anakinra, in the treatment of acute gouty arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/28\">",
"       28",
"      </a>",
"      ]. Ten subjects who had either failed or could not tolerate alternative antiinflammatory treatment received anakinra (100 mg) subcutaneously for three days, and were evaluated by tender and swollen joint counts and by subjective estimations of pain relief after three days and 30 days. In all 10 subjects, the acute inflammatory arthritis responded favorably (pain improvement 50 to 100 percent; clinical evaluation concordant) within 24 to 48 hours. No adverse effects were reported.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"       Canakinumab",
"      </a>",
"      &mdash; Canakinumab (ACZ2885), a fully humanized monoclonal antibody that blocks IL-1&beta; signaling, was effective for the treatment of acute gout in patients with a history of multiple flares and either refractoriness or contraindication to acute flare treatment with NSAIDs or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/29\">",
"       29",
"      </a>",
"      ]. In this phase 2 randomized trial a series of single subcutaneous doses of canakinumab were compared with intramuscularly administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide (TA) for efficacy and safety in treatment of acute gout flare pain, levels of acute phase reactants, and flare recurrence over a period of 60 days from onset of treatment.",
"      <br/>",
"      <br/>",
"      All five doses of canakinumab used (range 10 to 150 mg) resulted in numerically greater pain reduction compared with TA (40 mg); thus, the dose of canakinumab resulting in pain reduction equivalent to that achieved with TA could not be identified. However, a dose-dependent response was observed for canakinumab. Significant pain relief at 72 hours was shown for the 150 mg dose of the IL-1&beta; inhibitor; at this dose, pain relief was more prompt than with TA. Both CRP and SAA levels also decreased promptly in patients receiving the IL-1&beta; inhibitor. The relative risk of flare recurrence over the 60 days following 150 mg canakinumab injection was reduced by 94 percent compared with that following TA administration. No significant safety signals emerged in this trial. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of acute gout (or gout flare prophylaxis) with IL-1 inhibition remains off-label and cannot currently be recommended. Further studies are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPECIAL CIRCUMSTANCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic tophaceous gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute attacks of gout are treated in the same way for patients with and without clinically apparent tophi. Long-term management to prevent chronic gouty arthropathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hospitalized patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relatively common problem is the development of acute gouty arthritis in hospitalized (often postoperative) patients receiving no oral feedings. Treatment options in this setting include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intraarticular glucocorticoids",
"     </li>",
"     <li>",
"      Intravenous glucocorticoids",
"     </li>",
"     <li>",
"      Intramuscular or subcutaneous ACTH",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (in rare circumstances)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These therapies are described in more detail above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although renal insufficiency predisposes to hyperuricemia and gout, patients with advanced chronic kidney disease or end-stage renal disease requiring maintenance dialysis may be at lesser risk of symptomatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/24/17800/abstract/30\">",
"     30",
"    </a>",
"    ]. Such patients can be safely treated with intraarticular or oral glucocorticoids as described above.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    is generally avoided and, in patients not yet on dialysis, there is concern about worsening renal function with an NSAID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Renal transplant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gout can be a particular problem in patients who have undergone renal transplantation due to both reduced uric acid excretion and the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . Treatment of gout in this setting is challenging, in part due to complex and potentially serious drug interactions. As a result, gout in organ transplant recipients should only be managed by physicians experienced with these clinical problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=see_link\">",
"     \"Hyperuricemia and gout in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PATIENTS TAKING ANTIHYPERURICEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have had recurrent attacks of acute gouty arthritis, antihyperuricemic therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29668?source=see_link\">",
"     febuxostat",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/38/41572?source=see_link\">",
"     pegloticase",
"    </a>",
"    ) is used for long-term prophylaxis but has no role in the treatment of active gouty inflammation. However, once treatment with an antihyperuricemic agent has been initiated, most authorities believe that it should not be interrupted during an acute attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to appreciate the distinction between antiinflammatory therapy and antihyperuricemic therapy is frequently responsible for prolongation of the symptomatic state in patients whose gout should be readily controlled. Such patients should be treated for the acute attack the same way as patients who are not taking antihyperuricemic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=see_link\">",
"       \"Patient information: Gout (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"       \"Patient information: Gout (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for therapy in acute gout are limited by a lack of randomized, placebo-controlled trials. Nevertheless, general recommendations for treatment of acute gout based upon the available data are shown in the figure and are summarized briefly below (",
"    <a class=\"graphic graphic_algorithm graphicRef65843 \" href=\"UTD.htm?24/44/25295\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of therapy in an acute gout attack is prompt and safe termination of pain and disability. While symptoms will resolve without therapy within a few days to several weeks, symptoms improve more quickly with administration of any of a broad array of antiinflammatory drugs, with the most prompt and complete resolution occurring the earlier treatment is introduced.",
"     </li>",
"     <li>",
"      We recommend nonsteroidal antiinflammatory drugs (NSAIDs) as first line therapy for most patients with acute gout who have no contraindications to their use (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In the absence of data suggesting greater efficacy of one NSAID versus another, we often administer a potent NSAID (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      500 mg twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      50 mg three times daily) for reduction of acute gouty inflammation, especially if treatment is initiated within 24 hours of the onset of symptoms. In an attack of several days duration a longer course of treatment may be necessary and an antiinflammatory agent with fewer gastroduodenal side effects (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/18/39208?source=see_link\">",
"       nabumetone",
"      </a>",
"      or a selective COX-2 inhibitor) may be preferred.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is usually avoided because of the paradoxical effects of salicylates on serum urate. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'NSAIDs/COX-2 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      is effective for acute gout. In patients intolerant of NSAIDs and for whom glucocorticoid therapy is not appropriate, or for those who have used colchicine with success in the past, and in the absence of contraindications, we suggest the use of oral colchicine (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Colchicine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who cannot take NSAIDs or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      and who are not candidates for intraarticular corticosteroid injection because of polyarticular disease, we suggest use of oral glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We often use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      in doses of 30 to 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (or other equivalent glucocorticoid) for one to two days, then taper over seven to ten days. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucocorticoids'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Treatment options in patients who are unable to take oral medications include intraarticular or intravenous glucocorticoids, intramuscular or subcutaneous ACTH, and in locales where it is still available, cautious use of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients unable to take oral medications, with only one or two actively inflamed joints, and in whom infection has been ruled out, we suggest intraarticular injection of glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       Triamcinolone",
"      </a>",
"      acetonide, 40 mg for a large joint (eg, knee), 30 mg for medium joints (wrist, ankle, elbow) and 10 mg for small \"spaces\" can be used, or an equivalent dose of depo-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Intraarticular'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with polyarticular involvement, existing or easily established intravenous access, and no contraindications to glucocorticoids, we suggest systemic administration of a parenteral glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The dose and frequency depend upon the agent chosen. A typical dose is 20 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      twice daily, with stepwise reduction by half of each dose when improvement begins and maintenance of at least 4 mg twice daily (or oral equivalent) for 5 days. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with no intravenous access, intramuscular or subcutaneous ACTH may be used if it is readily available. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Systemic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the use of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      has been associated with serious systemic adverse effects (including death) in 2008 the US FDA asked manufacturers to cease making and shipping intravenous preparations in the USA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Colchicine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are taking antihyperuricemic therapy due to previous episodes of acute gout should be warned that antihyperuricemic therapy alone is not effective should they experience a recurrence of acute symptoms. Therapeutic recommendations for acute attacks in these patients are the same as in patients not taking antihyperuricemic therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patients taking antihyperuricemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interleukin-1 inhibition, including use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"       canakinumab",
"      </a>",
"      , has been effective in some cases, but additional studies are needed to better assess the usefulness and safety of this currently off-label approach, and it is not recommended at this time. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Interleukin-1 inhibition (investigational)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/1\">",
"      Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 1988; 14:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/2\">",
"      Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review. Rheumatology (Oxford) 2006; 45:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/3\">",
"      Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/4\">",
"      Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/5\">",
"      Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/6\">",
"      Lomen PL, Turner LF, Lamborn KR, et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986; 80:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/7\">",
"      Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15:1422.",
"     </a>",
"    </li>",
"    <li>",
"     Colcrys FDA Approval Letter. file://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022351s000ltr.pdf. Accessed February 10, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/9\">",
"      Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62:1060.",
"     </a>",
"    </li>",
"    <li>",
"     Colcrys (colchicine USP) Medication Guide. Revision 02, September 2009. Mutual Pharmaceutical Company, Inc., Philadelphia, PA 19124 USA. (approved by the U.S. Food and Drug Administration).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/11\">",
"      Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/12\">",
"      Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312.",
"     </a>",
"    </li>",
"    <li>",
"     FDA takes action to stop the marketing of unapproved injectable drugs containing colchicine. www.fda.gov/bbs/topics/news/2008/new01791.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/14\">",
"      Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine--guidelines for use. J Rheumatol 1988; 15:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/15\">",
"      Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002; 22:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/16\">",
"      Ferrannini E, Pentimone F. Marrow aplasia following colchicine treatment for gouty arthritis. Clin Exp Rheumatol 1984; 2:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/17\">",
"      Freeman DL. Frequent doses of intravenous colchicine can be lethal. N Engl J Med 1983; 309:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/18\">",
"      Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39:1203.",
"     </a>",
"    </li>",
"    <li>",
"     P450 Drug interaction table. file://medicine.iupui.edu/clinpharm/ddis/ClinicalTable.asp (Accessed June 7, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/20\">",
"      Fern&aacute;ndez C, Noguera R, Gonz&aacute;lez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/21\">",
"      Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/22\">",
"      Getting SJ, Christian HC, Flower RJ, Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002; 46:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/23\">",
"      Ritter J, Kerr LD, Valeriano-Marcet J, Spiera H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/24\">",
"      Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/25\">",
"      Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003; 349:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/26\">",
"      Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005; 52:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/27\">",
"      Martinon F, P&eacute;trilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/28\">",
"      So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/29\">",
"      So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/24/17800/abstract/30\">",
"      Ifudu O, Tan CC, Dulin AL, et al. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis 1994; 23:347.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1666 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17800=[""].join("\n");
var outline_f17_24_17800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NSAIDS/COX-2 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COLCHICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Oral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Traditional regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lower dose regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intravenous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intraarticular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Systemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interleukin-1 inhibition (investigational)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPECIAL CIRCUMSTANCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic tophaceous gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hospitalized patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Renal transplant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PATIENTS TAKING ANTIHYPERURICEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1666\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1666|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/44/25295\" title=\"algorithm 1\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1666|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 1\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/14/3303?source=related_link\">",
"      Hyperuricemia and gout in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28344?source=related_link\">",
"      Pathophysiology of gouty arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=related_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=related_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_24_17801="Pentobarbital: Pediatric drug information";
var content_f17_24_17801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentobarbital: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"    see \"Pentobarbital: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/7/38003?source=see_link\">",
"    see \"Pentobarbital: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nembutal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nembutal&reg; Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       General Anesthetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"      see \"Pentobarbital: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dose based on patient's age, weight, and medical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Consider the potential for delayed metabolism or elimination in infants &lt;6 months of age (Krauss, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypnotic:",
"     </b>",
"     Children: I.M.: 2-6 mg/kg; maximum dose: 100 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Preoperative sedation:",
"     </b>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 2-6 mg/kg; maximum dose: 100 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 1-3 mg/kg to a maximum of 100 mg to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Procedural (moderate) sedation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: Oral: 4 mg/kg, if needed supplemental 2-4 mg/kg every 30 minutes; maximum total dose: 8 mg/kg (Mason, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.M.: 2-6 mg/kg; maximum dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: Initial 1-2 mg/kg; additional doses of 1-2 mg/kg every 3-5 minutes to desired effect; usual effective total dose: 1-6 mg/kg (maximum: 100 mg/dose) (Krauss, 2006; Mason, 2004).",
"     <b>",
"      Note:",
"     </b>",
"     Patients receiving concurrent barbiturate therapy may require higher  total mg/kg doses (up to 9 mg/kg) (Mason, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: Oral, Rectal: (Krauss, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;4 years: 3-6 mg/kg; maximum dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;4 years: 1.5-3 mg/kg; maximum dose: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: I.V.: 100 mg prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reduction of elevated ICP:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Intubation is required; adjust dose based on hemodynamics, ICP, cerebral perfusion pressure, and EEG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Low dose: Children and Adolescents: 5 mg/kg every 4-6 hours (Mazzola, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-dose pentobarbital coma: Children and Adolescents: Loading dose: 10 mg/kg over 30 minutes, then 5 mg/kg every hour for 3 hours; initial maintenance infusion: 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; adjust to maintain burst suppression on EEG; maintenance dose range: 1-2 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (Adelson, 2003; Rangel-Castillo, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sedation of mechanically ventilated ICU patient (who failed standard therapy):",
"     </b>",
"     I.V.: Infants, Children, and Adolescents:  Loading dose: 1 mg/kg followed by 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     infusion. Additional boluses at a dose equal to hourly rate may be given every 2 hours as needed. If &ge;4-6 boluses are administered within 24 hours, then increase maintenance rate by 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; reported required range: 1-6 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (median: 2 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ). Tapering of dose and/or conversion to oral phenobarbital has been reported for therapy &ge;5 days (Tobias, 1995; Tobias, 2000; Tobias 2000a).",
"     <b>",
"      Note:",
"     </b>",
"     Higher rates of adverse effects were observed in a small report that used higher loading and initial maintenance doses (Yanay, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Status epilepticus refractory to standard therapy:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Intubation is required; adjust dose based on hemodynamics, seizure activity, and EEG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Infants, Children, and Adolescents: Loading dose: 5 mg/kg; maintenance infusion: Initial: 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     , may increase up to 3 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (usual range: 1-3 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); maintain burst suppression on EEG for 12-48 hours (no seizure activity), tapering pentobarbital rate by 0.5 mg/kg every 12 hours has been reported (Abend, 2008; Holmes, 1999; Kim, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-dose pentobarbital coma: I.V.: Infants and Children: Loading dose: 10-15 mg/kg given slowly over 1-2 hours; monitor blood pressure and respiratory rate. Maintenance infusion: Initial: 1 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ; may increase up to 5 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     (usual range: 0.5-3 mg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ); maintain burst suppression on EEG (Holmes, 1999).",
"     <b>",
"      Note:",
"     </b>",
"     Loading doses of 20-35 mg/kg (given over 1-2 hours) have been utilized in pediatric patients for pentobarbital coma, but these higher loading doses often cause hypotension requiring vasopressor therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypnotic/sedative:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 150-200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial: 100 mg; decrease dose for elderly or debilitated patients. If needed, may administer additional increments after at least 1 minute, up to a total dose of 200-500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Refractory status epilepticus:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Intubation required; adjust dose based on hemodynamics, seizure activity, and EEG (Abou Khaled 2008; Millikan, 2009; Mirski, 2008; Yaffe, 1993). Various regimens available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: 10-15 mg/kg (5-10 mg/kg in patients with pre-existing hypotension) administer slowly over 1 hour; initial maintenance infusion: 0.5-1 mg/kg/hour; adjust to maintain burst suppression pattern on EEG; maintenance dose range: 0.5-5 mg/kg/hour (Yaffe, 1993).",
"     <b>",
"      Note:",
"     </b>",
"     Patients may require infusion rates up to 10 mg/kg/hour (Abou Khaled, 2008; Mirski, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: 5 mg/kg (up to 25-50 mg/minute); repeat 5 mg/kg boluses until seizures stop; maintenance dose: 1 mg/kg/hour (range: 0.5-10 mg/kg/hour) (Abou Khaled, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     When increasing maintenance infusion rate during active seizure activity, some experts suggest administration of an additional 5 mg/kg bolus, given the long half-life of pentobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nembutal&reg;: 50 mg/mL (20 mL, 50 mL) [contains ethanol 10%, propylene glycol 40%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F208202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Intramuscular administration should be deep and in a large muscle to avoid tissue irritation. Adults: Do not exceed 5 mL volume at one injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Do not inject &gt;50 mg/minute; rapid I.V. injection may cause respiratory depression, apnea, laryngospasm, bronchospasm, and hypotension; administer over 10-30 minutes; maximum concentration: 50 mg/mL for slow I.V. push; may dilute in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, LR, Ringer's injection, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, and dextrose/saline combinations for continuous infusion. Solution highly alkaline (pH=9.5); care should be taken to avoid extravasation; consider administration using large bore vein (not hand or wrist) or via a running I.V. line at port farthest from patient's vein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Parenteral solution may be mixed with cherry syrup in 3:1 ratio (Mason, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F208208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, insulin (regular), linezolid, propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, fenoldopam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aminophylline, ephedrine, hyaluronidase, hydromorphone, neostigmine, scopolamine, sodium bicarbonate, thiopental.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Butorphanol, chlorpromazine, cimetidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, meperidine, midazolam, nalbuphine, pentazocine, prochlorperazine edisylate, promethazine, ranitidine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Atropine, morphine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); brief excursions of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) permitted. Avoid excessive heat; protect from freezing. Aqueous solutions are alkaline and are unstable; low pH may cause precipitate; use only clear solution",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedation, preanesthetic, short-term treatment of insomnia, and emergency treatment of acute convulsive episodes associated with certain conditions such as status epilepticus, eclampsia, tetanus, cholera, meningitis, and toxic reactions to local anesthetics or strychnine [FDA approved in pediatric patients (age not specified) and adults]; has also been used for procedural sedation (parenteral, oral, and rectal), treatment of increased intracranial pressure, and sedation for the mechanically ventilated ICU patient",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PENTobarbital may be confused with PHENobarbital",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nembutal&reg; may be confused with Myambutol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F208207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, agitation, anxiety, ataxia, CNS excitation, confusion, depression, dizziness, drowsiness, fever, hallucinations, headache, hyperkinesia, insomnia, nervousness, nightmares, psychiatric disturbances, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, exfoliative dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Megaloblastic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea (especially with rapid I.V. use), hypoventilation, laryngospasm, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Gangrene with inadvertent intra-arterial injection, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to barbiturates or any component; manifest or latent porphyria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with acute or chronic pain; may cause paradoxical responses, including agitation and hyperactivity, particularly in patients with acute pain and in pediatric patients. Use with caution and reduce the dose in patients with hepatic impairment; do not use in patients with hepatic coma. Use with caution in patients who are debilitated and those with hypovolemic shock, or heart failure.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolerance and/or psychological and physical dependence may occur; abrupt discontinuation after prolonged use may result in withdrawal symptoms, seizures, or status epilepticus; withdraw gradually if used over extended periods of time. Rapid I.V. administration may cause respiratory depression, apnea, laryngospasm, or hypotension (requiring vasopressor support). Pentobarbital may cause CNS depression; effects with alcohol or other sedative drugs may be potentiated. Patients require continuous monitoring and possibly airway management; cardiovascular and respiratory resuscitation equipment should be available with use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Parenteral solutions are highly alkaline; local tissue irritation and damage (with resultant necrosis) may result from perivascular extravasation; unintentional intra-arterial administration may cause a wide scope of adverse effects ranging from transient pain to gangrene of the limb; discontinue intravenous injection immediately with onset of burning and/or pain and evaluate for arterial injection or perivascular extravasation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection contains 10% alcohol and 40% propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates. One case report described an adult patient who developed lactic acidosis possibly secondary to propylene glycol accumulation following a continuous infusion of pentobarbital (Miller, 2008). Consider monitoring for signs of propylene glycol toxicity (eg, lactic acidosis, acute renal failure, osmol gap) in patients who require a continuous infusion of pentobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F208195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     High doses of pyridoxine may decrease drug effect; barbiturates may increase the metabolism of vitamins D and K; dietary requirements of vitamins D, K, C, B",
"     <sub>",
"      12",
"     </sub>",
"     , folate, and calcium may be increased with long-term use",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10580824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates can be detected in the placenta, fetal liver and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate including seizures and hyperirritability; symptoms may be delayed up to 14 days. Use during labor does not impair uterine activity; however, respiratory depression may occur in the newborn; resuscitation equipment should be available, especially for premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, respiratory status (including pulse oximetry for moderate sedation), cardiovascular status, CNS status. Monitor EEG when using pentobarbital to treat status epilepticus or to reduce ICP. Monitor ICP and cerebral perfusion pressure (CPP) (CPP = MAP - ICP) when using pentobarbital coma to reduce ICP. Consider monitoring for signs of propylene glycol toxicity (eg, lactic acidosis, acute renal failure, osmolal gap) in patients who require a continuous infusion of pentobarbital. Periodically monitor renal, hepatic, and hematopoietic function with prolonged therapy.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1054824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypnotic: 1-5 mcg/mL (SI: 4-22 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Coma: 20-50 mcg/mL (SI: 88-221 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: &gt;10 mcg/mL (SI: &gt;44 &mu;mol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-acting barbiturate with sedative, hypnotic, and anticonvulsant properties; depresses CNS activity by binding to barbiturate site at GABA-receptor complex enhancing GABA activity; depresses reticular activating system; higher doses may be gabamimetic",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Values below are for sedation in pediatric and adult patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (Krauss, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 10-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Almost immediate, within 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, Rectal: 15-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (Krauss, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral, Rectal: 1-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.8 L/kg (Schiable, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1 L/kg (Ehrnebo, 1974)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 45% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via hydroxylation and glucuronidation (Wermeling, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 26 &plusmn; 16 hours (Schaible, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults (healthy): 22 hours (15-50 hours, dose-dependent) (Ehrnebo, 1974)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1 % excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/7/38003?source=see_link\">",
"      see \"Pentobarbital: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine; may be habit-forming; avoid abrupt discontinuation after prolonged use; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tolerance to hypnotic effect can occur; taper dose to prevent withdrawal; in pediatric patients, a total cumulative pentobarbital dose &ge;25 mg/kg or duration &ge;5-7 days have been reported to have a higher probability of withdrawal. To prevent withdrawal in susceptible pediatric patients, the following dosing approach transitioning to PHENobarbital has been described:  Discontinue PENTobarbital infusion, administer half of the PHENobarbital I.V. loading dose (see table) over 1 hour followed 6 hours later by the remaining half of PHENObarbital loading dose I.V. (over 1 hour).  Begin maintenance  PHENobarbital dose 6 hours after loading dose completed; the maintenance PHENobarbital dose should be",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of the initial loading dose I.V. given every 12 hours. Once patient is stabilized, may switch to oral therapy and begin tapering 10% to 20% weekly (Tobias, 2000; Tobias, 2000a).",
"     <b>",
"      Note:",
"     </b>",
"     This conversion method is based on preliminary data and further studies are needed to confirm the efficacy of this regimen.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         PENTobarbital Infusion Rate (mg/kg/hour)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         PHENobarbital I.V. Loading Dose (mg/kg)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abend NS and Dlugos DJ, \"Treatment of Refractory Status Epilepticus: Literature Review and a Proposed Protocol,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2008, 38(6):377-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/18486818/pubmed\" id=\"18486818\" target=\"_blank\">",
"        18486818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abou Khaled KJ and Hirsch LJ, \"Updates in the Management of Seizures and Status Epilepticus in Critically Ill Patients,\"",
"      <i>",
"       Neurol Clin",
"      </i>",
"      , 2008, 26(2):385-408.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/18514819/pubmed\" id=\"18514819\" target=\"_blank\">",
"        18514819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Adelson PD, Bratton SL, Carney NA, et al, \"Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents. Chapter 13. The Use of Barbiturates in the Control of Intracranial Hypertension in Severe Pediatric Traumatic Brain Injury,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2003, 4(3 Suppl):S49-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/12847349/pubmed\" id=\"12847349\" target=\"_blank\">",
"        12847349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, et al, \"Guidelines for the Management of Severe Traumatic Brain Injury. XI. Anesthetics, Analgesics, and Sedatives,\"",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24 Suppl 1:S71-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/17511550/pubmed\" id=\"17511550\" target=\"_blank\">",
"        17511550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, and Joint Section on Neurotrauma and Critical Care, \"Use of Barbiturates in the Control of Intracranial Hypertension,\"",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2000, 17(6-7):527-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/10937896/pubmed\" id=\"10937896\" target=\"_blank\">",
"        10937896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ehrnebo M, \"Pharmacokinetics and Distribution Properties of Pentobarbital in Humans Following Oral and Intravenous Administration,\"",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1974, 63(7):1114-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/4853598/pubmed\" id=\"4853598\" target=\"_blank\">",
"        4853598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer JH and Raineri DL, &ldquo;Pentobarbital Anesthesia for Status Epilepticus,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1987, 6(8):601-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/3691007/pubmed\" id=\"3691007\" target=\"_blank\">",
"        3691007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes GL and Riviello JJ, \"Midazolam and Pentobarbital for Refractory Status Epilepticus,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1999, 20(4):259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/10328273/pubmed\" id=\"10328273\" target=\"_blank\">",
"        10328273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim SJ, Lee DY, and Kim JS, \"Neurologic Outcomes of Pediatric Epileptic Patients With Pentobarbital Coma,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2001, 25(3):217-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/11587876/pubmed\" id=\"11587876\" target=\"_blank\">",
"        11587876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krauss B and Green SM, \"Procedural Sedation and Analgesia in Children,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9512):766-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/16517277/pubmed\" id=\"16517277\" target=\"_blank\">",
"        16517277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mason KP, Zurakowski D, Connor L, et al, \"Infant Sedation for MR Imaging and CT: Oral Versus Intravenous Pentobarbital,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2004, 233(3):723-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/15516603/pubmed\" id=\"15516603\" target=\"_blank\">",
"        15516603",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mazzola CA and Adelson PD, \"Critical Care Management of Head Trauma in Children,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(11 Suppl):S393-401.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/12528780/pubmed\" id=\"12528780\" target=\"_blank\">",
"        12528780",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller MA, Forni A, and Yogaratnam D, \"Propylene Glycol-Induced Lactic Acidosis in a Patient Receiving Continuous Infusion Pentobarbital,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(10):1502-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/18698010/pubmed\" id=\"18698010\" target=\"_blank\">",
"        18698010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Millikan D, Rice B, and Silbergleit R, \"Emergency Treatment of Status Epilepticus: Current Thinking,\"",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2009, 27(1):101-13, ix.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/19218022/pubmed\" id=\"19218022\" target=\"_blank\">",
"        19218022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pereira JK, Burrows PE, Richards HM, et al, &ldquo;Comparison of Sedation Regimens for Pediatric Outpatient CT,&rdquo;",
"      <i>",
"       Pediatr Radiol",
"      </i>",
"      , 1993, 23(5):341-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/8233681/pubmed\" id=\"8233681\" target=\"_blank\">",
"        8233681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rangel-Castilla L, Gopinath S, and Robertson CS, \"Management of Intracranial Hypertension,\"",
"      <i>",
"       Neurol Clin",
"      </i>",
"      , 2008, 26(2):521-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/18514825/pubmed\" id=\"18514825\" target=\"_blank\">",
"        18514825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaible DH, Cupit GC, Swedlow DB, et al, &ldquo;High-Dose Pentobarbital Pharmacokinetics in Hypothermic Brain-Injured Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1982, 100(4):655-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/7062221/pubmed\" id=\"7062221\" target=\"_blank\">",
"        7062221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, \"Pentobarbital for Sedation During Mechanical Ventilation in the Pediatric ICU Patient,\"",
"      <i>",
"       J Intensive Care Med",
"      </i>",
"      , 2000, 15:115-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, \"Tolerance, Withdrawal, and Physical Dependency After Long-Term Sedation and Analgesia of Children in the Pediatric Intensive Care Unit,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2000a, 28(6):2122-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/10890677/pubmed\" id=\"10890677\" target=\"_blank\">",
"        10890677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobias JD, Deshpande JK, Pietsch JB, et al, &ldquo;Pentobarbital Sedation for Patients in the Pediatric Intensive Care Unit,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1995, 88(3):290-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/7886524/pubmed\" id=\"7886524\" target=\"_blank\">",
"        7886524",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wermeling D, Record K, Bell R, et al, \"Hemodialysis Clearance of Pentobarbital During Continuous Infusion,\"",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1985, 7(4):485-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/4082247/pubmed\" id=\"4082247\" target=\"_blank\">",
"        4082247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaffe K and Lowenstein DH, \"Prognostic Factors of Pentobarbital Therapy for Refractory Generalized Status Epilepticus,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1993, 43(5):895-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/8492944/pubmed\" id=\"8492944\" target=\"_blank\">",
"        8492944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yanay O, Brogan TV, and Martin LD, \"Continuous Pentobarbital Infusion in Children Is Associated With High Rates of Complications,\"",
"      <i>",
"       J Crit Care",
"      </i>",
"      , 2004, 19(3):174-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/24/17801/abstract-text/15484178/pubmed\" id=\"15484178\" target=\"_blank\">",
"        15484178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12693 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17801=[""].join("\n");
var outline_f17_24_17801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208174\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208175\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054820\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054812\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208152\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208136\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208202\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054826\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208208\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054815\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054825\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208210\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208207\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054830\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054811\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054810\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208195\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208145\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054833\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208147\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10580824\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054819\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054824\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054809\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054828\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054829\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054817\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054831\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12693|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=related_link\">",
"      Pentobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/7/38003?source=related_link\">",
"      Pentobarbital: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_24_17802="Gastritis intestinal metaplasia";
var content_f17_24_17802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1110px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Incomplete intestinal metaplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view (H&amp;E stain) of chronic gastritis with incomplete intestinal metaplasia showing metaplastic goblet cells in the surface and foveolar epithelium (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Normal gastric antrum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Normal surface (SE) and foveolar epithelium (FE) and glands (G). Right panel: Higher power view of the glands shows mucous cells (M) and gastrin-secreting endocrine cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17802=[""].join("\n");
var outline_f17_24_17802=null;
var title_f17_24_17803="Blood flow at rest and exercise";
var content_f17_24_17803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blood flow distribution at rest and at maximal exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rest (percent total)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximal exercise (percent total)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splanchnic",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal muscle",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kidneys",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other organs",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17803=[""].join("\n");
var outline_f17_24_17803=null;
var title_f17_24_17804="Drivers with CHD risk";
var content_f17_24_17804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with risk for CHD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Asymptomatic, healthy",
"      </td>",
"      <td>",
"       <p>",
"        Low CHD event risk.",
"       </p>",
"       <p>",
"        Assess for clinically apparent risk factors.",
"       </p>",
"       <p>",
"        Use, when possible, Framingham risk score model to predict 10-year CHD event risk",
"       </p>",
"       <p>",
"        Increasing age is a surrogate marker for increasing atherosclerotic plaque burden",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Yes, if asymptomatic.",
"       </p>",
"       <p>",
"        Rarely disqualifying alone.",
"       </p>",
"      </td>",
"      <td>",
"       Biennial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       <p>",
"        Asymptomatic, high risk person (as designated by CHD risk-equivalent condition)*",
"       </p>",
"       <p>",
"        Asymptomatic, high risk person &gt;45 years with multiple risk factors for CHD",
"       </p>",
"      </td>",
"      <td rowspan=\"5\">",
"       <p>",
"        Sub-clinical coronary atherosclerosis is a concern",
"       </p>",
"       <p>",
"        High-risk status requires close physician follow-up and aggressive comprehensive risk factor management",
"       </p>",
"      </td>",
"      <td>",
"       Yes, if asymptomatic.",
"      </td>",
"      <td rowspan=\"5\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       No if:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Abnormal ETT&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Ischemic changes on ECG&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Functional incapacitation by one of conditions.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * CHD risk equivalent is defined as presence of diabetes mellitus, peripheral vascular disease, or Framingham risk score predicting a 20 percent CHD event risk over the next 10 years.",
"     <br>",
"      &bull; Abnormal ETT is defined by an inability to exceed 6 METS (beyond completion of Stage II, or 6 minutes) on a standard Bruce protocol or the presence of ischemic symptoms and/or signs (eg, characteristic angina pain or 1 mm ST depression or elevation in 2 or more leads), inappropriate SBP and/or heart rate responses (eg, inability in the maximal heart rate to meet or exceed 85 percent of age-predicted maximal heart rate), or ventricular dysrhthymia.",
"      <br>",
"       &Delta; Ischemic ECG changes are defined by the presence of new 1 mm ST-segment elevation or depression and/or marked T wave abnormality.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17804=[""].join("\n");
var outline_f17_24_17804=null;
var title_f17_24_17805="Treatment of macular edema";
var content_f17_24_17805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photocoagulation for macular edema slows progression to severe visual loss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative rate of developing severe visual loss in untreated eyes with macular edema and eyes treated with focal laser therapy. Photocoagulation slowed the rate of severe visual loss.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.&nbsp;Ophthalmology 1991; 98:766.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17805=[""].join("\n");
var outline_f17_24_17805=null;
var title_f17_24_17806="Tongue atrophy and fasciculations in ALS";
var content_f17_24_17806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/63510/alstnfsc_conv.mp4?title=Tongue+atrophy+and+fasciculations+in+ALS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tongue atrophy and fasciculations in a patient with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is tongue atrophy and weakness. Tongue fasciculations and the characteristic \"can of worms\" appearance are evident. The patient has difficult protruding the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nestor Galvez-Jimenez, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17806=[""].join("\n");
var outline_f17_24_17806=null;
var title_f17_24_17807="Mobilization of the upper rectum";
var content_f17_24_17807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobilization of the upper rectum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper rectum&nbsp;is mobilized with the sigmoid colon &nbsp;in the avascular plane, gently sweeping the bowel anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_24_17807=[""].join("\n");
var outline_f17_24_17807=null;
